- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06272578
Screen CardRen - A Cross-sectional Observational Cohort Study
A Cross-sectional Observational Cohort Study to Evaluate the Prevalence of Asymptomatic Cardiac Structural Abnormalities and Cardiac Dysfunction in a Contemporary Outpatient at Risk Population With Chronic Kidney Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background/Rationale:
Chronic kidney disease and cardiovascular disease share a large set of risk factors, such as arterial hypertension, type 2 diabetes mellitus and dyslipidaemia. Chronic kidney disease, even in early stages, further increases the risk for cardiovascular diseases such as heart failure.
Objectives and Hypotheses:
In this single-centre, cross-sectional study, the investigators will aim to assess the prevalence of asymptomatic echocardiographic structural and functional cardiac abnormalities in adult CKD patients with additional cardiovascular risk factors. Furthermore, with the use of Olink technology, analyses of the plasma proteome will be performed to identify potential protein pathways associated with early structural changes. The investigators hypothesize that protein expression will be altered in patients with prevalent echocardiographic abnormalities that indicate stage B heart failure.
Methods:
Study design: single-centre, cross-sectional, non-interventional study Data Source(s): electronic case report form containing patient history, clinical status and physical examination, imaging data from echocardiography, air displacement plethysmography data, plasma proteome data obtained from Olink technology-based analysis of blood samples Study Population: Adult chronic kidney disease patients with additional cardiovascular risk factors (at least one of the following: arterial hypertension, type 2 diabetes mellitus, and dyslipidaemia). The inclusion criteria are further defined in the corresponding section of the study protocol.
Exposure(s): chronic kidney disease and cardiovascular risk factors such as arterial hypertension, type 2 diabetes mellitus, dyslipidaemia, or atherosclerotic vascular disease
Outcome(s):
Primary objective:
• Assess the frequency of stage B heart failure as indicated by structural or functional cardiac abnormalities assessed by echocardiography and/or corresponding laboratory parameters
Secondary objectives:
- Identification of possible predictive parameters for significant cardiac dysfunction (Heart Failure Stage B) in a contemporary at risk cohort with renal dysfunction, based on imaging and proteomics data
- Building of the Berlin-Brandenburg prevention network to improve the intersectional cooperation to identify, diagnose and follow-up risk patients
- Establishment of tools like US.2 AI, electronic health records, central data management in order to enable a fast construction while working resource-friendly
- Follow-up of risk patients based on mobile sensors/apps
- Adoption of screening in standard care Sample Size Estimations: The study is focused on the estimation of the prevalence of significant asymptomatic cardiac structural abnormalities and cardiac dysfunction in a contemporary at risk cohort with chronic kidney disease. Therefore, the investigators will calculate the corresponding two-sided 95% confidence interval. With a sample size of 400 patients, a two-sided 95% confidence interval for an assumed prevalence of 30% can be determined with an extension of ± 4%.
Statistical Analysis:
Objectives will be analyzed according to their scaling and distribution characteristics, including appropriate descriptive location and variability parameters and 95% confidence intervals. Additionally, multiple regression analyses will be performed in order to identify potential risk factors for significant cardiac dysfunction.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Daniela Zurkan
- Phone Number: +49 30 450 665 374
- Email: daniela.zurkan@dhzc-charite.de
Study Contact Backup
- Name: Friederike Fenske
- Phone Number: +49 30 450 653 782
- Email: friederike.fenske@dhzc-charite.de
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
The study population will comprise 400 adult patients with chronic kidney disease, defined as elevated urine albumin to creatinine ratio (UACR > 30 mg/g or >3 mg/mmol) or reduced estimated glomerular filtration rate (eGFR < 60 ml/min/1.73m²) at a one-time measurement.
In addition to renal function impairment, study participants will either have a background of cardiovascular risk factors, including arterial hypertension, type 2 diabetes mellitus or hypercholesterolemia.
Description
Inclusion Criteria:
Chronic Kidney Disease, stages G1-G4, AND
- Estimated glomerular filtration rate (eGFR) as determined by the 2009 CKD-EPI Cr equation ≥ 60 ml/min/1.73m², if UACR ≥30 mg/g (≥3 mg/mmol) OR
- eGFR according to CKD-EPI 2009 Cr equation < 60 ml/min/1.73m², but > 15 ml/min/1.73m²
Diabetes mellitus type 2 OR
- Pathological findings in oral glucose tolerance test (≥ 200 mg/dl (2h)) OR
- documented HbA1c ≥ 6.5 % OR
- Intake of any antidiabetic medication (in case of previously established diagnosis of Diabetes mellitus type 2) OR
- Fasting blood glucose ≥ 126 mg/dl
Arterial Hypertension Grade ≥ 1 OR
- Blood pressure of ≥ 140/90 mmHg, defined according to the 2018 ESC guidelines on arterial hypertension (Williams) OR
- Intake of antihypertensive drugs
Hypercholesterolemia OR
- LDL-cholesterol > 130mg/dl OR
- Intake of a lipid-lowering medication initiated to treat dyslipoptroteinemia
Exclusion Criteria:
History of acute kidney injury > stage 1 according to KDIGO criteria in the two weeks prior to study visit
- Chronic kidney disease Stage 5 (end-stage renal disease)
- Previous diagnosis of chronic heart failure
- Acute myocardial infarction in the past 30 days prior to study visit
- Stroke in the past 30 days prior to study visit
- Known congenital heart disease
- Previous diagnosis of a specific cardiomyopathy, infiltrative cardiac disease, pericardial constriction, sarcoidosis, amyloidosis and other storage diseases
- Implanted cardiac devices, such as pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization devices
- Implanted mechanical valve prosthesis
- Inability to give informed consent
- Lack of health insurance
- Organ transplanted
- Intake of immunosuppressive medication
- Major surgery in the 6 months before study visit, such as cardiac bypass surgery or valve replacement surgery (thoracotomy), major vascular surgery (such as replacement of aortic root, ascending part, aortic arch or any part of the abdominal aorta), major abdominal surgery (e.g. Whipple procedure, colorectal resection, gastrectomy and others) or limb amputation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prevalence of significant asymptomatic cardiac structural abnormalities and cardiac dysfunction
Time Frame: 1 year
|
Transthoracic echocardiographic measurements are the primary outcome parameters and will be conducted according to the current recommendations for cardiac chamber quantification of the American Society of Echocardiography and the European Association of Cardiovascular Imaging, the latest update on left ventricular diastolic function assessment and recommendations on aortic stenosis quantification.
|
1 year
|
Proteomic analysis
Time Frame: 1 year
|
Proteomic analysis will be performed using Olink technology, which is based on proximity extension assay (PEA) technology combined with next generation sequencing.
This method has demonstrated accuracy and sensitivity in detecting minute quantities of proteins (sub-pg/ml), making it suitable for conducting extensive multiplex assays covering a wide dynamic range.
In this study, plasma samples
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of echocardiographic examination
Time Frame: 1 year
|
The duration of echocardiographic examination as mean, median, standard deviation, quantiles and range in comparison between portable and cart-based device
|
1 year
|
Time saved by portable echocardiography and automated image analysis
Time Frame: 1 year
|
Amount of time savings in minutes as mean, median, standard deviation, quantiles and range in comparison between portable device and automated image analysis, potential impact on waiting period for patients requiring echocardiography
|
1 year
|
Image quality of cart-based vs. portable echo images
Time Frame: 1 year
|
The number of echocardiographic examinations with acceptable image quality as frequencies and percentages in comparison between devices
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Frank Edelmann, Prof. Dr., Deutsches Herzzentrum der Charité
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20021405
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on Echocardiography
-
Kang YanRecruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingNon-valvular Atrial Fibrillation | Embolic StrokeChina
-
Assiut UniversityUnknownCORONARY ARTERY BYPASSEgypt
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityUnknownMyocardial Infarction | Left Ventricular Dysfunction | Echocardiography 2DEgypt
-
Milton S. Hershey Medical CenterCompletedEchocardiography, Transesophageal | Ventricular Function, RightUnited States
-
Weill Medical College of Cornell UniversityWithdrawn3D Transesophageal and Transthoracic EchocardiogramUnited States
-
London North West Healthcare NHS TrustRecruitingCoronary Artery DiseaseUnited Kingdom
-
Papworth Hospital NHS Foundation TrustUnknownChronic Thromboembolic Pulmonary Hypertension
-
Assiut UniversityNot yet recruiting